The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Highlights from MPN sessions
Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, summarizes some interesting highlights from the myeloproliferative neoplasm (MPN) sessions at ASH 2021. Dr Rampal draws focus on the number of therapeutic agents that are progressing in the treatment landscape of rare diseases including myelofibrosis, essential thrombocythemia, polycythemia vera, mastocytosis, and FGFR1-rearranged myeloid lymphoid disease. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
